| Methods |
2‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐109 mm Hg, within 10 mm Hg on 2 consecutive weekly visits during run‐in; 4‐week double‐blind treatment |
| Participants |
All patients: n=42(27 males,15 females); all white;
Cilazapril 2.5 mg: n=14; mean age=53.6(8.0) years; baseline sitting SBP=153.6(16.4) mm Hg, DBP=102.0(4.7) mm Hg;
Cilazapril 5 mg: n=14; mean age=53.1(8.2) years; baseline sitting SBP=154.8(15.1) mm Hg, DBP=101.0(4.3) mm Hg;
Placebo: n=14; mean age=55.1(7.7) years; baseline sitting SBP=157.5(15.8) mm Hg, DBP=101.1(3.8) mm Hg |
| Interventions |
Cilazapril 2.5 mg once daily;
Cilazapril 5 mg once daily;
Placebo;
taken in the morning |
| Outcomes |
Trough sitting SBP/DBP using mercury sphygmomanometer |
| Notes |
BP change and SD of change not reported, endpoint BP reported, endpoint SD not reported; baseline SBP SD reported, imputed baseline SBP SD for SBP SD of change, imputed overall trial mean DBP SD of change; BP data from Table 1, p. 914; Jadad score=3; funding source= Hoffman‐La Roche Ltd. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
